Filing Flows › Health Care › Talphera (TLPH)
Talphera (TLPH) earnings and revenue breakdown
Latest: Q3 2025 · 10-Q filed Nov 12, 2025 · Talphera (TLPH) Q3 2025 earnings results →
Talphera made $1K in Q3 2025. Operating margin n/m, net loss $4.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 12, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1K in Q3 2025.
Operating costs exceeded revenue by $3.4M, an operating margin of -342200.0%. The quarter ended with a net loss of $4.4M.
Operating cash flow was −$2.5M. Non-cash charges added back $152K of share-based compensation. Working capital and other items added $1.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2025 | 10-Q | Nov 12, 2025 | $1K | — | n/m | −$4.4M | −$2.5M |
| Q1 2025 | 10-Q | May 14, 2025 | $27K | — | n/m | −$2.6M | −$3.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Talphera
We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Our portfolio is principally focused on our lead product candidate, Niyad (nafamostat mesylate), for use as a regional anticoagulant during continuous renal replacement therapy, or CRRT. In addition, we may develop LTX-608, a nafamostat formulation for direct IV infusion for one or more of the following indications: disseminated intravascular coagulation, or DIC, acute respiratory distress syndrome, or ARDS, acute pancreatitis, or as an anti-viral treatment. We have two pre-filled syringe product candidates that have been explored but are being evaluated for discontinuation.
In its own words, from its 10-K, filed Mar 23, 2026.
Talphera against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| TLPH Talphera | Q3 2025 | $1K | — | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Talphera 10-Q on SEC EDGAR · CIK 1427925 · Pharmaceutical Preparations
13F: who owns TLPH and who is buying
More on TLPH
History
Every quarter: Q3 2025 results · Q1 2025 results